查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1574866

郁血性心臟衰竭药物市场规模、份额、趋势分析报告：按药物、产品、通路、地区、细分市场预测，2024-2030年

Congestive Heart Failure Drugs Market Size, Share & Trends Analysis Report By Drug (ACE Inhibitors, Angiotensin 2 Receptor Blockers), By Product (Injection, Capsule and Tablets), By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10个工作天内

价格
简介目录

郁血性心臟衰竭药物市场成长与趋势：

预计2030年全球郁血性心臟衰竭药物市场规模将达198.5亿美元，2024年至2030年复合年增长率为14.6%。

郁血性心臟衰竭（CHF）盛行率的增加、人口老化导致疾病风险增加以及更好的治疗方法的研究和开发的增加是推动成长的主要因素。 2020年，全球约有6,434万人患有心臟衰竭。此外，糖尿病和高血压等疾病的估计盛行率也很高。

加强研究和开发以获得更好的治疗方法是多种产品出现在管道中的一个主要因素。诺和诺德的 Semaglutide、Zensun 的 Neucardin、拜耳的 vericiguat 和阿斯特捷利康的 AZD4831 都是着名的候选药物。此外，钠-葡萄糖共同输送体2 (SGLT2) 抑制剂治疗 CHF 的扩大适应症的核准预计将推动市场成长。例如，2022年2月， Jardiance（Empagliflozin）和2020年5月，Farxiga（Dapagliflozin）作为CHF治疗药物获得了扩大的适应症。

阿斯特捷利康（AstraZeneca）、百时美施贵宝公司（Bristol-Myers Squibb Company）、安进（Amgen Inc.）和勃林格殷格翰（Boehringer Ingelheim）等主要企业正在新兴国家和经济优势地区通过併购、监管核准、联盟和伙伴关係关係策略性地寻求地域扩张。例如，2021年2月，阿斯特捷利康宣布在中国核准Farxiga（Dapagliflozin）用于患有和不患有第2型糖尿病患者的CHF适应症。在中国之前，该药已在美国、欧洲和日本核准用于相同适应症。

COVID-19 影响了药品的供需，使患者难以获得医疗保健，并减少了大流行期间对产品的需求。随着法规的实施，研究和开发阻碍了临床试验程序。但疫情过后，该产业加快了步伐。

郁血性心臟衰竭市场报告亮点

  • 2021年，由于高处方率和市场渗透率，ACE抑制剂细分市场占据最大份额。
  • 按药物类别划分，由于钠-葡萄糖共同输送体2 (SGLT2) 抑制剂的推出，预计其他细分市场在预测期内将成长最快。
  • 从分销管道来看，由于零售药房与居家医疗环境和处方药的密切亲和性，预计在预测期内将出现良好的成长。
  • 北美郁血性心臟衰竭市场2023年占最大份额，达37.6%。这是由于主要企业的存在、有利的财政支持以及意识提升。

目录

第一章调查方法和范围

第 2 章执行摘要

第三章郁血性心臟衰竭药物市场变数、趋势与范围

  • 市场介绍/系统展望
  • 市场规模及成长前景
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 郁血性心臟衰竭药物市场分析工具
    • 波特的分析
    • PESTEL分析

第四章郁血性心臟衰竭药物市场：药物估计与趋势分析

  • 细分仪表板
  • 郁血性心臟衰竭市场：药物变化分析，百万美元，2023 年和 2030 年
  • ACE抑制剂
  • 血管收缩素2受体阻断剂
  • β受体阻断剂
  • 利尿剂
  • 醛固酮拮抗剂
  • 强心药
  • 其他的

第五章郁血性心臟衰竭药物市场：产品估算与趋势分析

  • 细分仪表板
  • 郁血性心臟衰竭市场：产品变化分析，百万美元，2023 年和 2030 年
  • 注射
  • 胶囊
  • 药片

第六章郁血性心臟衰竭药物市场：通路估算与趋势分析

  • 细分仪表板
  • 郁血性心臟衰竭药物市场：分销管道波动分析，百万美元，2023 年和 2030 年
  • 医院
  • 零售药房
  • 网路药房

第七章郁血性心臟衰竭药物市场：区域估计与趋势分析

  • 2023 年和 2030 年按地区分類的郁血性心臟衰竭市场占有率，百万美元
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东/非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第八章 竞争格局

  • 最新趋势与影响分析：主要市场参与企业
  • 公司分类
  • 企业热力图分析
  • 公司简介
    • Bayer AG
    • Novartis AG
    • Merck & Co., Inc.
    • AstraZeneca
    • Bristol-Myers Squibb Company
    • Amgen Inc.
    • Boehringer Ingelheim International GmbH
    • Pfizer, Inc.
    • Johnson & Johnson Services, Inc.
    • Otsuka Pharmaceutical Co., Ltd.
    • Eli Lilly and Company
    • Novo Nordisk A/S
简介目录
Product Code: GVR-4-68039-987-5

Congestive Heart Failure Drugs Market Growth & Trends:

The global Congestive Heart Failure drugs market size is expected to reach USD 19.85 billion in 2030 and is projected to grow at a CAGR of 14.6% from 2024 to 2030. The increase in the prevalence of congestive heart failure (CHF), the rising aging population leading to increased risk of disease, and growing research and development for better treatment approaches are the key factors augmenting the growth. In 2020, around 64.34 million people worldwide were suffering from heart failure. In addition, its estimated prevalence rate is high in patients with diseases such as diabetes and hypertension.

Increasing research and development for better treatment options is a major factor behind the presence of multiple products in the pipeline. Novo Nordisk's Semaglutide, Zensun's Neucardin, Bayer's vericiguat, and AstraZeneca's AZD4831 are among the prominent drug candidates. Moreover, approval of an extended label for sodium-glucose co-transporter 2 (SGLT2) inhibitors for CHF is expected to fuel market growth. For instance, in February 2022, Jardiance (empagliflozin) and in May 2020, Farxiga (dapagliflozin) received label expansion for the treatment of CHF.

Key players such as AstraZeneca; Bristol-Myers Squibb Company; Amgen Inc.; and Boehringer Ingelheim are strategically engaged in geographical expansions, regulatory approvals, collaborations, and partnerships through mergers and acquisitions in emerging and economically favorable regions. For instance, in February 2021, AstraZeneca announced the approval of Forxiga (dapagliflozin) in China, indicated for CHF with or without type-2 diabetes. Before China, the drug was already approved in the U.S., Europe, and Japan for the same indication.

COVID-19 impacted the demand and supply of drugs, and patients faced difficulty in healthcare access, resulting in a decline in product demand amid the pandemic. Due to imposed restrictions, research and development saw a setback in clinical trial proceedings. However, after the pandemic, the industry regained its pace.

Congestive Heart Failure Drugs Market Report Highlights:

  • In 2021, the ACE inhibitors segment held the largest share due to its high prescription rate and market penetration
  • By drug class, the others segment is expected to be the fastest-growing segment over the forecast period due to the launch of sodium-glucose co-transporter 2 (SGLT2) inhibitors
  • By distribution channel, the retail pharmacies segment is expected to witness lucrative growth over the forecast period due to its high compatibility with home care settings and prescription drugs
  • North America congestive heart failure drugs market held the largest share of 37.6% in 2023. This can be attributed to the presence of key players, favorable funding assistance, and increased patient awareness

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Congestive Heart Failure Drugs Market Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
  • 3.4. Congestive Heart Failure Drugs Market Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. Congestive Heart Failure Drugs Market: Drug Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Congestive Heart Failure Drugs Market: Drug Movement Analysis, USD Million, 2023 & 2030
  • 4.3. ACE Inhibitors
    • 4.3.1. ACE Inhibitors Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Angiotensin 2 Receptor Blockers
    • 4.4.1. Angiotensin 2 Receptor Blockers Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Beta Blockers
    • 4.5.1. Beta Blockers Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. Diuretics
    • 4.6.1. Diuretics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.7. Aldosterone antagonists
    • 4.7.1. Aldosterone antagonists Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.8. Inotropes
    • 4.8.1. Inotropes Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.9. Others
    • 4.9.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Congestive Heart Failure Drugs Market: Product Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Congestive Heart Failure Drugs Market: Product Movement Analysis, USD Million, 2023 & 2030
  • 5.3. Injection
    • 5.3.1. Injection Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Capsule
    • 5.4.1. Capsule Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5. Tablets
    • 5.5.1. Tablets Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Congestive Heart Failure Drugs Market: Distribution Channel Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Congestive Heart Failure Drugs Market: Distribution Channel Movement Analysis, USD Million, 2023 & 2030
  • 6.3. Hospitals
    • 6.3.1. Hospitals Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Retail Pharmacies
    • 6.4.1. Retail Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Online Pharmacies
    • 6.5.1. Online Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Congestive Heart Failure Drugs Market: Regional Estimates & Trend Analysis

  • 7.1. Congestive Heart Failure Drugs Market Share, By Region, 2023 & 2030, USD Million
  • 7.2. North America
    • 7.2.1. North America Congestive Heart Failure Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.2. U.S.
      • 7.2.2.1. U.S. Congestive Heart Failure Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.3. Canada
      • 7.2.3.1. Canada Congestive Heart Failure Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.4. Mexico
      • 7.2.4.1. Mexico Congestive Heart Failure Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3. Europe
    • 7.3.1. Europe Congestive Heart Failure Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.2. UK
      • 7.3.2.1. UK Congestive Heart Failure Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.3. Germany
      • 7.3.3.1. Germany Congestive Heart Failure Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.4. France
      • 7.3.4.1. France Congestive Heart Failure Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.5. Italy
      • 7.3.5.1. Italy Congestive Heart Failure Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.6. Spain
      • 7.3.6.1. Spain Congestive Heart Failure Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.7. Denmark
      • 7.3.7.1. Denmark Congestive Heart Failure Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.8. Sweden
      • 7.3.8.1. Sweden Congestive Heart Failure Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.9. Norway
      • 7.3.9.1. Norway Congestive Heart Failure Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific Congestive Heart Failure Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.2. China
      • 7.4.2.1. China Congestive Heart Failure Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.3. Japan
      • 7.4.3.1. Japan Congestive Heart Failure Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.4. India
      • 7.4.4.1. India Congestive Heart Failure Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.5. South Korea
      • 7.4.5.1. South Korea Congestive Heart Failure Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.6. Australia
      • 7.4.6.1. Australia Congestive Heart Failure Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.7. Thailand
      • 7.4.7.1. Thailand Congestive Heart Failure Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Latin America
    • 7.5.1. Latin America Congestive Heart Failure Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.2. Brazil
      • 7.5.2.1. Brazil Congestive Heart Failure Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.3. Argentina
      • 7.5.3.1. Argentina Congestive Heart Failure Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6. Middle East and Africa
    • 7.6.1. Middle East and Africa Congestive Heart Failure Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.2. South Africa
      • 7.6.2.1. South Africa Congestive Heart Failure Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.3. Saudi Arabia
      • 7.6.3.1. Saudi Arabia Congestive Heart Failure Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.4. UAE
      • 7.6.4.1. UAE Congestive Heart Failure Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.5. Kuwait
      • 7.6.5.1. Kuwait Congestive Heart Failure Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis by Key Market Participants
  • 8.2. Company Categorization
  • 8.3. Company Heat Map Analysis
  • 8.4. Company Profiles
    • 8.4.1. Bayer AG
      • 8.4.1.1. Participant's Overview
      • 8.4.1.2. Financial Performance
      • 8.4.1.3. Product Benchmarking
      • 8.4.1.4. Recent Developments/ Strategic Initiatives
    • 8.4.2. Novartis AG
      • 8.4.2.1. Participant's Overview
      • 8.4.2.2. Financial Performance
      • 8.4.2.3. Product Benchmarking
      • 8.4.2.4. Recent Developments/ Strategic Initiatives
    • 8.4.3. Merck & Co., Inc.
      • 8.4.3.1. Participant's Overview
      • 8.4.3.2. Financial Performance
      • 8.4.3.3. Product Benchmarking
      • 8.4.3.4. Recent Developments/ Strategic Initiatives
    • 8.4.4. AstraZeneca
      • 8.4.4.1. Participant's Overview
      • 8.4.4.2. Financial Performance
      • 8.4.4.3. Product Benchmarking
      • 8.4.4.4. Recent Developments/ Strategic Initiatives
    • 8.4.5. Bristol-Myers Squibb Company
      • 8.4.5.1. Participant's Overview
      • 8.4.5.2. Financial Performance
      • 8.4.5.3. Product Benchmarking
      • 8.4.5.4. Recent Developments/ Strategic Initiatives
    • 8.4.6. Amgen Inc.
      • 8.4.6.1. Participant's Overview
      • 8.4.6.2. Financial Performance
      • 8.4.6.3. Product Benchmarking
      • 8.4.6.4. Recent Developments/ Strategic Initiatives
    • 8.4.7. Boehringer Ingelheim International GmbH
      • 8.4.7.1. Participant's Overview
      • 8.4.7.2. Financial Performance
      • 8.4.7.3. Product Benchmarking
      • 8.4.7.4. Recent Developments/ Strategic Initiatives
    • 8.4.8. Pfizer, Inc.
      • 8.4.8.1. Participant's Overview
      • 8.4.8.2. Financial Performance
      • 8.4.8.3. Product Benchmarking
      • 8.4.8.4. Recent Developments/ Strategic Initiatives
    • 8.4.9. Johnson & Johnson Services, Inc.
      • 8.4.9.1. Participant's Overview
      • 8.4.9.2. Financial Performance
      • 8.4.9.3. Product Benchmarking
      • 8.4.9.4. Recent Developments/ Strategic Initiatives
    • 8.4.10. Otsuka Pharmaceutical Co., Ltd.
      • 8.4.10.1. Participant's Overview
      • 8.4.10.2. Financial Performance
      • 8.4.10.3. Product Benchmarking
      • 8.4.10.4. Recent Developments/ Strategic Initiatives
    • 8.4.11. Eli Lilly and Company
      • 8.4.11.1. Participant's Overview
      • 8.4.11.2. Financial Performance
      • 8.4.11.3. Product Benchmarking
      • 8.4.11.4. Recent Developments/ Strategic Initiatives
    • 8.4.12. Novo Nordisk A/S
      • 8.4.12.1. Participant's Overview
      • 8.4.12.2. Financial Performance
      • 8.4.12.3. Product Benchmarking
      • 8.4.12.4. Recent Developments/ Strategic Initiatives